Our team

As graduate of HEC Paris and Columbia Business School, Mr. Moretti worked for 10 years in the banking sector, before founding the industrial holding Dynaction listed on the Paris stock exchange.

He then focused on the development of one of the holding’s subsidiaries, PCAS Biosolution, which he managed as CEO for 13 years and enabled it to become the European leader in the chemistry of complex molecules, employing more than 1,000 people worldwide.

In addition to his extensive experience in the financial and industrial fields, Mr. Moretti has a deep knowledge of Mithra’s strategic and operational priorities, since he has been on its Board of Directors for more than 3 years.

Mr. Erik Van Den Eynden graduated in Economics at the University of Antwerp and has more than 30 years of experience in the banking sector.

He joined ING in 1990, where he held various commercial and management positions, including District Manager, Head of MidCorporates & Institutionals, CEO of ING Insurance Belgium & Luxembourg. From 2017 to 2020, he held the position of CEO of ING Belgium. In March 2021, Mr. Van Den Eynden became CEO of the Straco Investment Group active in real estate project development, investments and private equity.

Ms. An Cloet holds a Master's degree in Pharmacy from the University of Leuven and a Degree in Business and Administration from the University of Louvain.

She has over 25 years of pharmaceutical experience in multiple therapeutic domains, in particular women's health (contraception, osteoporosis, fertility). She built her career within MSD, where she has held various positions in Business Development, Marketing and Corporate Strategy. Since 2019, Ms Cloet is External Affairs Director at MSD Belux.

Ms. Patricia van Dijck holds a degree in medicine and a specialization in clinical biology and pharmaceutical medicine from the Catholic University of Louvain (UCL).

She began her career in the pharmaceutical industry in 1996 as an International Medical Advisor at UCB. She then became Medical Director at Lundbeck, before being appointed Managing Director in 2007. In 2011, Mrs. van Dijck joined Novartis Belux as Head of Market Access & Public Affairs, before joining the mother company in Basel in 2014 as Head Patient Access Excellence. Since 2018, she has been working for GSK Belux as Market Access & Public Affairs Director.

Ms. Liesbeth Weynants holds a master’s degree in law from the University of Leuven and is specialized in pharmaceutical and regulatory law with a focus on the life sciences sector.

She has extensive expertise in intellectual property and patent law for innovative medicines (AbbVie, Allergan, Biogen, Boehringer Ingelheim, Celgene, J&J, Lundbeck, Merck, Novartis, Sanofi...) and is currently Managing Partner at the law firm Hoyng Rokh Monegier as well as Professor of Intellectual Property Law at the VUB.

Ms. Valérie Gordenne holds a Master's degree in Pharmacy from the University of Liège.

She has over 20 years of experience in pharmaceutical Research & Development with extensive leadership experience in full drug development across a range of therapeutic areas, in particular in women's health (CSO Mithra, CEO Novalon, General Manager Odyssea). Through the management of various functions and activities, she has developed a deep operational and strategic knowledge and expertise in drug development. She is currently Chief Scientific Officer at Auxin Surgery, CEO of the start-up Odix and advisor in regulatory affairs.

Mr. Gaëtan Servais graduated in economics from the University of Liege, where he started his career as a research assistant.

In 1995, he joined the Federal Planning Bureau as an expert and later the Economic and Social Council of the Walloon Region. In 2001, he became Chief of Staff for several ministers of the Walloon government. Since 2007, he has been CEO of the Liège-based investment fund Noshaq, which offers financing solutions for the creation and growth of companies.

Ms. Amel Tounsi holds a PhD in Biomedical and Pharmaceutical Sciences from the University of Louvain.

She has a broad experience in cell-therapy development. During her career in the biotech sector (Celyad, Texere, Analis, Masthercell), she acquired a strong expertise in Business Development and Company Development strategy. Since January 2021, she works as an Investment Manager at the Liège-based investment fund Noshaq.

Professor Jean-Michel Foidart graduated in Gynecology from the University of Liège and also obtained a PhD in cell biology and biochemistry, before directing its Department of Gynecology-Obstetrics.

Co-founder of Mithra, he is the author of more than 1300 publications on women’s health and experimental oncology. Professor Foidart holds the Francqui Chair, Doctor Honoris Causa of the Pierre and Marie Curie University of Paris and the Paul Sabatier University of Toulouse. He is Officer of the Order of Leopold II, Commander, Grand Officer of the Order of the Crown, Professor Extraordinary, Honorary of the ULg and Perpetual Secretary of the Royal Academy of Medicine of Belgium. He was also General Secretary of the European Society of Gynecology and member of multiple editorial boards of international peer-reviewed journals.